FDA/Alliance for NanoHealth Nanotechnology Initiative (FANTI)
Nanoengineered products are poised to impact all products under FDA’s jurisdiction. While there are demonstrated benefits of these products, there remain unanswered questions about how these products may behave in complex biological systems. In this regard, FDA is interested in understanding the risks and benefits of nanoengineered medical products, and to expanding the body of information to facilitate the regulatory review and evaluation of new products that incorporate nanotechnology platforms and nanoscale particles.
One of the collaborative efforts FDA is engaged in is collaboration with the Houston-based Alliance for NanoHealth (ANH) and its eight member institutions to help speed development of safe and effective medical products in the emerging field of nanotechnology.
Under a Memorandum of Understanding, the FDA/ANH Nanotechnology Initiative will work to expand knowledge of how nanoparticles behave and affect biologic systems, and to facilitate the development of tests and processes that might mitigate the risks associated with nanoengineered products. All outcomes from this public-private partnership will be placed in the public domain for the benefit of all stakeholders
The eight academic institutions include Baylor College of Medicine, the University of Texas’ M.D. Anderson Cancer Center, Rice University, the University of Houston, the University of Texas Health Science Center at Houston, Texas A & M Health Science Center, the University of Texas Medical Branch at Galveston, and the Methodist Hospital Research Institute.
For more information about FANTI visit MOU 225-07-8006 and "FDA and Eight Academic and Research Institutions to Collaborate Under Nanotechnology Initiative" (FDA Press Release).